- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Otonomy is a biotechnology business based in the US. Otonomy shares (OTIC) are listed on the PINK and all prices are listed in US Dollars. Otonomy employs 51 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Otonomy stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
How to buy Otonomy stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – OTIC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Otonomy stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Otonomy stock price (PINK: OTIC)
Use our graph to track the performance of OTIC stocks over time.Otonomy shares at a glance
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $0.11 |
200-day moving average | $0.36 |
Wall St. target price | $9.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.06 |
Otonomy financials
Gross profit TTM | $-245,000 |
---|---|
Return on assets TTM | -38.12% |
Return on equity TTM | -118.86% |
Profit margin | 0% |
Book value | $0.38 |
Market Capitalization | $582,482 |
TTM: trailing 12 months
Otonomy share dividends
We're not expecting Otonomy to pay a dividend over the next 12 months.
Otonomy share price volatility
Over the last 12 months, Otonomy's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Otonomy's is 1.5717. This would suggest that Otonomy's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Otonomy overview
Otonomy, Inc. , a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Frequently asked questions
What percentage of Otonomy is owned by insiders or institutions?Currently 7.668% of Otonomy shares are held by insiders and 1.427% by institutions. How many people work for Otonomy?
Latest data suggests 51 work at Otonomy. When does the fiscal year end for Otonomy?
Otonomy's fiscal year ends in December. Where is Otonomy based?
Otonomy's address is: 4796 Executive Drive, San Diego, CA, United States, 92121 What is Otonomy's ISIN number?
Otonomy's international securities identification number is: US68906L1052 What is Otonomy's CUSIP number?
Otonomy's Committee on Uniform Securities Identification Procedures number is: 68906L105
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question